Navigation Links
Bioheart Announces Acceptance of Marvel-1 Data for Presentation at the Heart Failure Society of America (HFSA) Meeting
Date:7/23/2009

SUNRISE, Fla., July 23 /PRNewswire-FirstCall/ -- Bioheart, Inc. (OTC Bulletin Board: BHRT) a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases announced today acceptance of MARVEL-1 data for presentation at the Heart Failure Society of America (HFSA) Meeting September 13-16th, 2009 in Boston, Massachusetts.

Chris O'Connor, MD, Head of Heart Failure at Duke University and Thomas Povsic, MD, Ph.D., Assistant Professor of Medicine at Duke University will present the final data for Part 1 of the MARVEL Phase II/III Clinical Trial as a part of the Late Breaking Clinical Trials Session on September 16, 2009.

Doug Owens, RN, MPH, CCRA, Director of Clinical and Regulatory Affairs, at Bioheart, Inc., states "We are very excited about the positive results we have seen in the Marvel-Part 1 study and look forward to presenting the final data. We are eager to launch part two of the MARVEL Study and anticipate rapid enrollment upon re-initiation of the trial."

Bioheart, Inc. is committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases. Its goals are to improve a patient's quality of life and reduce health care costs and hospitalizations. Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its lead product candidate, MyoCell((R)), is an innovative clinical muscle-derived stem cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. The Company's pipeline includes multiple product candidates for the treatment of heart damage, including Bioheart Acute Cell Therapy, an autologous, adipose tissue-derived stem cell treatment for acute heart damage, and MyoCell((R)) SDF-1, a therapy utilizing autologous cells that are genetically modified to express additional potentially therapeutic growth proteins. For more information on Bioheart, visit www.bioheartinc.com.

MyoCell, MyoCell SDF-1 and MyoCath are trademarks of Bioheart, Inc.

Forward-Looking Statements:

Except for historical matters contained herein, statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would", "estimate", or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Investors and others are cautioned that a variety of factors, including certain risks, may affect our business and cause actual results to differ materially from those set forth in the forward-looking statements. These risk factors include, without limitation, (i) our ability to obtain additional financing; (ii) our ability to control and reduce our expenses; (iii) our ability to establish a distribution network for and commence distribution of certain products for which we have acquired distribution rights; (iv) our ability to timely and successfully complete our clinical trials; (v) the occurrence of any unacceptable side effects during or after preclinical and clinical testing of our product candidates; (vi) the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; (vii) our dependence on the success of our lead product candidate; (viii) our inability to predict the extent of our future losses or if or when we will become profitable; (ix) our ability to protect our intellectual property rights; and (x) intense competition. The Company is also subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2008, as amended by its Annual Report on Form 10-K/A, and its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2008; June 30, 2008 and September 30, 2008.

    Contact:
    At the Company:
          Howard J. Leonhardt, Chief Executive Officer
          (954) 835-1500

    Investor Relations:

          RedChip Companies, Inc.
          Dave Gentry, (800) 733-2447, Ext. 104
          info@redchip.com


'/>"/>
SOURCE Bioheart, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Bioheart, Inc. Announces Receipt of $2.8 Million in Proceeds From Pipe Financing
2. Bioheart to Introduce Improved Heart Failure Monitoring Systems at Heart Failure Nurses Annual Meeting
3. Snoring Isn't Sexy, LLC Announces Commendation Program to Honor Sleep Physicians Who Work with Dentists to Manage Sleep Breathing Disorders
4. Cell Therapeutics, Inc. Announces Public Offering of Common Stock and Warrants
5. Orexigen(R) Therapeutics Announces Proposed Public Offering of Common Stock
6. Human Genome Sciences Announces Second-Quarter 2009 Financial Results and Key Developments
7. Service Corporation International Announces Schedule For Its Second Quarter 2009 Earnings Release and Conference Call
8. Quigley Corporation Announces Final Results of Quigley Pharmas Phase IIb Study
9. TrinityCare Senior Living Announces Extension of Financing for Trinity Shores Facility in Port Lavaca, Texas
10. Cryo-Cell Announces Celle(SM) Research and Development Collaboration for Chronic Wound Healing Management
11. Nighttime Care Centers Announces New Urgent Care Medical Clinic in Montgomery County, Maryland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Alpharetta, Georgia (PRWEB) , ... February 11, 2016 ... ... Physicians Group (DMPG) will use the action analytics leader’s population health solutions, ... analytics and clinical support to the Atlanta-area healthcare system. Details of the contract ...
(Date:2/11/2016)... ... February 11, 2016 , ... Dr. Sadati’s ... of cosmetic procedures. Along with performing procedures, the magazine also highlights that Dr. ... cosmetic procedures. One of the most common procedures he performs is his natural ...
(Date:2/11/2016)... ... 2016 , ... Image One USA veteran franchise owner Maria Bogacki ... buildings of Nashville that will benefit. , “I’ve enjoyed being a part of the ... was no question that I would bring my business with me,” Bogacki said. “The ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... to reverse diabetes has been gearing up for their simultaneous grand openings in ... It’s about right now that you’re probably wondering, is reversing diabetes possible? According ...
(Date:2/11/2016)... ... February 11, 2016 , ... In a new paper ... surgeon , Dr. Rod J. Rohrich, and colleagues, examine and underscore the importance ... for rhinoplasty surgeons when addressing this vital area. , The upper lateral cartilage ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... 11, 2016  AfterPill.com is reporting that this week,s ... for all women who are at risk of unintended ... year and raises the risks of unprotected sex in ... According to the Guttmacher Institute, there are 43 ... child-bearing age, who have sex without the intention of ...
(Date:2/11/2016)... de fevereiro de 2016  A Proliant Biologicals ... de soroalbumina bovina (BSA -- Bovine Serum ... na Ilha Norte da Nova Zelândia, em Feilding. ... na fábrica da Proliant nos EUA, localizada em ... e instalação dos equipamentos foram feitos de forma ...
(Date:2/11/2016)... MEADOWS , Ill. and INDIANAPOLIS , ... milestone for many young people, but for those with ... Not only do these students juggle class schedules, assignments ... of living with type 1 diabetes. On top of ... first time. Diabetes Scholars Foundation (Foundation) ...
Breaking Medicine Technology: